Education

The hub for all your learning resources.

Here you will find all our clinical education resources from articles to recorded webinars, all supporting equitable access to funded medicines.

The jury is in – usual gout care isn’t working well, especially for Māori and Pacific peoples, who are disproportionately affected by this common disorder.

What potential tools are readily available to reduce gout harm? Specific clinician actions!  

Read the bulletin here.

Contributor
He Ako Hiringa
26 October 2021

Looking for up-to-date information on gout? You can find it here!

We’ve linked resources from multiple providers into one place so it’s easy for you to find what you need.

 

Contributor
He Ako Hiringa
18 October 2021
45 minutes to Delve

Following on from presentations in February, this new resource covers discussions from webinars held in August 2021.

The content has been edited, and reviewed by Waikato DHB endocrinologist/diabetologist Dr Ryan Paul.

We recommend using Google Chrome when accessing this resource. You may experience technical difficulties on other internet browsers.

Contributor
Dr Ryan Paul
13 October 2021
17 minutes to Listen

Introducing Legendary Conversations, our podcast series that explores aspects of primary care in Aotearoa New Zealand. In episode one (part 1), we talk with Professor Keith Petrie about the psychological effects of taking medicines, and what primary healthcare professionals need to know. 

Contributor
Professor Keith Petrie
11 October 2021
21 minutes to Read + 24 minutes to Delve

Linda Bryant discusses gout, a chronic long-term condition that is often associated with other diseases, and with drug-related morbidity and mortality. As such, it needs to be addressed holistically as part of the psychosocial medical model.

30 September 2021

Biological medicines have markedly changed prognoses for many conditions such as cancers, diabetes and autoimmune diseases.  

As biologics’ patents expire, biosimilars – highly similar versions of approved biologic brands – will be competitively marketed. This will lead to cost savings, increased access and treatment options, and improved patient outcomes.2

Read the HAH Bulletin to find out more.

Contributor
He Ako Hiringa
27 September 2021
8 minutes to Read

Patients can no longer be started on funded selegiline. Patients who were on selegiline prior to 1 August 2021 will need their prescriptions endorsed to receive subsidised supplies. An alternative MAO-B inhibitor, rasagiline, may be a suitable agent for new patients or those transitioning from selegiline.

This resource provides a timeline for the changes and information about transitioning patients from selegiline. Advice on prescribing rasagiline is also included.

Contributor
He Ako Hiringa
14 September 2021

Dulaglutide is available from 1 September, but do you know how to pronounce it? Listen to our quick guide for help.

Contributor
He Ako Hiringa
30 August 2021
15 minutes to Delve

From 1 September and when clinically indicated, dulaglutide can be started in adult patients with type 2 diabetes using the steps shown in this resource.

Talking points, relevant for all patients starting dulaglutide, are provided along with two algorithms and accompanying prescribing notes.

Contributor
Brendan Duck, Ryan Paul
25 August 2021
15 minutes to Delve

When clinically indicated, empagliflozin can be started in adult patients with type 2 diabetes using the steps shown in this resource (updated 24 Aug 2021).

Talking points, relevant for all patients starting empagliflozin, are provided along with two algorithms and accompanying prescribing notes. Which algorithm you follow will depend on your patient’s level of hypoglycaemia risk. 

Contributor
Brendan Duck, Ryan Paul
24 August 2021